Mary Fenton
Director/Board Member at Connecticut Business & Industry Association
Net worth: 155 835 $ as of 2024-03-30
Profile
Mary Kay Fenton is currently the Director at Connecticut Business & Industry Association.
She previously held positions as an Independent Director at Oncorus, Inc. from 2019 to 2023, Vice President-Strategic Operations at Vertex Pharmaceuticals, Inc. from 2019 to 2021, Senior Manager-Technology Industry Group at PricewaterhouseCoopers LLP from 1991 to 2000, CFO, Principal Accounting Officer & Executive VP at Achillion Pharmaceuticals, Inc. from 2000 to 2018, Chief Operating & Financial Officer at Semma Therapeutics, Inc. in 2019, and Chief Financial Officer at Talaris Therapeutics, Inc. from 2021 to 2023.
Ms. Fenton obtained an undergraduate degree from the College of the Holy Cross (Massachusetts) and an MBA from the University of Connecticut School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.03% | 2023-07-02 | 6,805 ( 0.03% ) | 155 835 $ | 2024-03-30 |
ONCORUS, INC.
-.--% | 2023-03-30 | 0 ( -.--% ) | - $ | 2023-12-30 |
Mary Fenton active positions
| Companies | Position | Start |
|---|---|---|
Connecticut Business & Industry Association
 Connecticut Business & Industry Association Miscellaneous Commercial ServicesCommercial Services Connecticut Business & Industry Association is a non-profit organization that provides commercial support services. The private company is based in Hartford, CT. Joseph F. Brennan has been the CEO of the company since 1988. | Director/Board Member | 2018-12-05 |
Former positions of Mary Fenton
| Companies | Position | End |
|---|---|---|
| ONCORUS, INC. | Director/Board Member | 2023-07-26 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2021-01-31 |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Director of Finance/CFO | 2019-09-30 |
| ACHILLION PHARMACEUTICALS, INC. | Director of Finance/CFO | 2018-12-27 |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Corporate Officer/Principal | 2000-09-30 |
Training of Mary Fenton
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| University of Connecticut School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| ONCORUS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Connecticut Business & Industry Association
Connecticut Business & Industry Association Miscellaneous Commercial ServicesCommercial Services Connecticut Business & Industry Association is a non-profit organization that provides commercial support services. The private company is based in Hartford, CT. Joseph F. Brennan has been the CEO of the company since 1988. | Commercial Services |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Talaris Therapeutics, Inc.
 Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA. | Health Technology |
- Stock Market
- Insiders
- Mary Fenton
